SEOM clinical guidelines for the treatment of metastatic breast cancer

被引：6

作者：

Alvarez Lopez, Isabel ^{[1
]}

de la Haba Rodriguez, Juan ^{[2
]}

Ruiz Simon, Amparo ^{[3
]}

Bellet Ezquerra, Meritxell ^{[4
]}

Calvo Martinez, Lourdes ^{[5
]}

Garcia Estevez, Laura ^{[6
]}

Rodriguez Lescure, Alvaro ^{[7
]}

Isla Casado, Dolores ^{[8
]}

机构：

[1] Hosp Donostia, Serv Oncol Med, ES-20014 Donostia San Sebastian, Spain

[2] Hosp Univ Reina Sofia, Serv Oncol Med, Cordoba, Spain

[3] Inst Valenciano Oncol, Serv Oncol Med, Valencia, Spain

[4] Hosp Gen Valle Hebron, Serv Oncol Med, Barcelona, Spain

[5] Complejo Hosp Univ, Serv Oncol Med, La Coruna, Spain

[6] Ctr Integral Oncol Clara Campal, Serv Oncol Med, Madrid, Spain

[7] Hosp Gen Univ Elche, Serv Oncol Med, Alicante, Spain

[8] Hosp Clin Univ Lozano Blesa, Serv Oncol Med, Zaragoza, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2010年 / 12卷 / 11期

关键词：

Metastatic; Breast; Cancer; Diagnostic; Treatment; POSTMENOPAUSAL WOMEN; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; PHASE-II; CHEMOTHERAPY; TRASTUZUMAB; PACLITAXEL; THERAPY; PLUS; METAANALYSIS;

D O I：

10.1007/s12094-010-0585-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with metastatic breast cancer have a wide number of treatment options, including medical, surgical, and supportive care measures. Treatment decisions are based in predictive and prognostic factors and the informed choice of the patients. SEOM has elaborated these guidelines with evidence-based recommendations for the diagnostic work-up, treatment (chemotherapy, endocrine therapy and targeted therapies) and supportive care for the management of these patients.

引用

页码：719 / 723

页数：5

共 18 条

[11] Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials [J].

Klijn, JGM ;

Blamey, RW ;

Boccardo, F ;

Tominaga, T ;

Duchateau, L ;

Sylvester, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :343-353

[12] Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group [J].

Marty, M ;

Cognetti, F ;

Maraninchi, D ;

Snyder, R ;

Mauriac, L ;

Tubiana-Hulin, M ;

Chan, S ;

Grimes, D ;

Antón, A ;

Lluch, A ;

Kennedy, J ;

O'Byrne, K ;

Conte, P ;

Green, M ;

Ward, C ;

Mayne, K ;

Extra, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4265-4274

[13] Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis [J].

Mauri, Davide ;

Pavlidis, Nicholas ;

Polyzos, Nikolaos P. ;

Ioannidis, John P. A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (18) :1285-1291

[14] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J].

Miller, Kathy ;

Wang, Molin ;

Gralow, Julie ;

Dickler, Maura ;

Cobleigh, Melody ;

Perez, Edith A. ;

Shenkier, Tamara ;

Cella, David ;

Davidson, Nancy E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) :2666-2676

[15] Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials [J].

Robertson, JFR ;

Osborne, CK ;

Howell, A ;

Jones, SE ;

Mauriac, L ;

Ellis, M ;

Kleeberg, UR ;

Come, SE ;

Vergote, I ;

Gertler, S ;

Buzdar, A ;

Webster, A ;

Morris, C .

CANCER, 2003, 98 (02) :229-238

[16] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[17] Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC breast group study [J].

Tomiak, E ;

Piccart, M ;

Mignolet, F ;

Sahmoud, T ;

Paridaens, R ;

Nooy, M ;

Beex, L ;

Fentiman, IS ;

Muller, A ;

vanderSchueren, E ;

Rubens, RD .

EUROPEAN JOURNAL OF CANCER, 1996, 32A (11) :1876-1887

[18]

VONMINCKWITZ G, 2008, J CLIN ONCOL S20, V26

← 1 2 →